相关实验视频

Updated: Jun 13, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

晚期肝细胞癌的管理:一篇综述和实用指南

Vishnu Nagalapuram¹, Niveditha Popuri², Ryan D Nipp¹

¹Division of Hematology/Oncology, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK.

JCO oncology practice

|March 3, 2025

概括

肝细胞癌 (HCC) 在全球范围内正在增加. 本综述涵盖了先进的HCC系统治疗的最新进展,包括免疫检查点抑制剂和氨酸激酶抑制剂,改善了患者的治疗结果.

科学领域:

肝病学和瘤学肝病学和瘤学
胃肠病学胃肠病学

背景情况:

全球肝细胞癌 (HCC) 的发病率和死亡率正在上升.
流行病学风险因素正在从病毒性肝炎转向酒精和与代谢功能障碍相关的脂肪性肝病.
超过一半的晚期HCC患者需要全身治疗.

研究的目的:

为了提供一个全面的概述的最新发展在系统治疗的先进的HCC.
更新实践瘤学家在不断变化的治疗环境.

主要方法:

审查最近的临床试验数据和治疗批准.
分析分子测试和肝功能在HCC管理中的当前作用.
讨论正在研究的新型全身疗法.

主要成果:

对于高级HCC的治疗环境随着新的批准而显著发展.
针对血管生成的免疫检查点抑制剂和氨酸激酶抑制剂改善了患者的治疗结果.
系统性药物的最佳测序仍然没有定义.

结论:

系统疗法已经改变了先进的HCC管理.
目前正在进行的研究正在探索新的治疗方式,如采用细胞疗法.
需要进一步的研究来确定最佳的治疗序列和分子测试的作用.

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Published on: May 2, 2025

相关概念视频

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment: